EE308 Real-World Treatment Patterns and Costs in Relapsed and Refractory Diffuse Large B-Cell Lymphoma in the United States

To examine real-world treatment patterns, healthcare resource utilization and costs among third-line (3L) relapsed refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients in the United States. A retrospective claims analysis was carried out using IBM® MarketScan® Database (Jan 2015-Dec 2019) to assess patterns adult DLBCL receiving 3L treatment. diagnosis of (ICD10 C83.X), ≥ 12 months pre-diagnosis baseline data with no anti-cancer treatments or other primary cancers, ≥3 follow-up were required for inclusion. Treatments received 3L, time next therapy (TTNT) % subsequent are described. Healthcare (HCRU) while on reported a per patient month (PPPM) basis. total 133 met inclusion criteria median 5.7 months. Median [IQR] age 57 [50, 62] years 59% male. Commonly therapies chemotherapy combination/monotherapy (20%), autologous stem cell transplant rituximab containing (17%), radiotherapy combination (11%) multitude combinations. TTNT 4.4 30% 4L, though period limited. As advanced from 1L proportion inpatient stays increased (32% 43%, respectively). PPPM more than doubled increasing as advance through lines $33,669 1L, $39,300 2L $72,224 3L. Costs largely driven by medical costs. Treatment options R/R heterogenous clear standard care. later lines, increased, underscoring need novel improve care patients.